Mergers & Acquisitions
By The Online Investor Staff, updated Thu., Mar. 28, 10:25 PM
This Slide: #4 of 100 |
Slide #4. Aeterna Zentaris Inc. — Ceapro Inc.
Acquirer:
Aeterna Zentaris Inc. (AEZS)
Acquiree:
Ceapro Inc. (CRPOF)
Details:
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS.CA) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the "Transaction").
Aeterna Zentaris is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Co.'s primary product, macimorelin, is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency. Macimorelin is marketed in the U.S. under the tradename Macrilen through a license agreement with Novo Nordisk.
Open the AEZS Page at The Online Investor »
Aeterna Zentaris is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Co.'s primary product, macimorelin, is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency. Macimorelin is marketed in the U.S. under the tradename Macrilen through a license agreement with Novo Nordisk.
Open the CRPOF Page at The Online Investor »
|
|
Free Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |